The Role of Neutrophil CD11b Compared to Neutrophil CD64 as an Early Diagnostic, Monitoring, and Prognostic Sepsis

Heba E Hashem1, Wafaa O Ahmed1, Safeya H Hassan1

  • 1Clinical Pathology Department, Ain Shams University Hospitals, Cairo, Egypt.

PubMed

Insights

Neutrophil CD64 (nCD64) shows superior diagnostic performance for neonatal sepsis compared to CD11b. Combining nCD64 with hs-CRP offers a rapid and accurate diagnostic tool for neonatal intensive care units (NICUs).

Area of Science:

  • Neonatal Medicine
  • Immunology
  • Biomarker Discovery

Background:

  • Neonatal sepsis poses significant risks, including mortality, neurodevelopmental disabilities, and lifelong morbidities.
  • Early diagnosis and treatment are critical to mitigate these severe consequences.

Purpose of the Study:

  • To evaluate the diagnostic and prognostic performance of CD11b as a sepsis biomarker in neonates.
  • To compare CD11b's efficacy against neutrophil CD64 (nCD64) and conventional sepsis parameters.

Main Methods:

  • A cohort of 211 neonates (101 controls, 110 sepsis) was studied in Egyptian NICUs.
  • Sepsis screening included CBC, hs-CRP, blood cultures, and flow cytometry for CD64 and CD11b on neutrophils.

Main Results:

  • Neutrophil CD64 percentage (nCD64%) demonstrated high diagnostic performance (92.8% sensitivity, 90.8% specificity, AUC=0.894).
  • CD11b showed poor diagnostic utility (CD11b% AUC=0.405, CD11b MFI AUC=0.144).
  • Combining hs-CRP and nCD64% yielded the highest diagnostic accuracy (93.9% sensitivity, 97.2% specificity, AUC=0.938).

Conclusions:

  • Neutrophil CD64% is a superior biomarker for neonatal sepsis compared to CD11b and hs-CRP alone.
  • Combined measurement of nCD64% and hs-CRP provides a highly accurate and rapid diagnostic method for neonatal sepsis.
  • Neutrophil CD64 can be routinely applied in NICUs for improved sepsis management.

Related Concept Videos